
Opinion|Videos|May 22, 2024
Payers Review Process and Effective Strategies for PDT Coverage
Paul Jeffrey, PharmD, presents the findings of a study, which investigated patient engagement and clinical outcomes associated with the use of prescription digital therapeutics (PDTs) in the treatment of substance use disorders, and discusses the need for further research to advance the efficacy and value of PDTs in this field.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
















































